Clinical Trials Logo

Gastro Esophageal Reflux clinical trials

View clinical trials related to Gastro Esophageal Reflux.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06430047 Recruiting - Clinical trials for Gastro Esophageal Reflux

Efficacy and Safety of EsoDuo®

Start date: November 25, 2022
Phase: Phase 4
Study type: Interventional

Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid

NCT ID: NCT06280664 Recruiting - Clinical trials for Gastro Esophageal Reflux

Efficacy Of Hiatal Closure For GERD

Start date: October 2, 2020
Phase:
Study type: Observational

The purpose of this protocol is to study the efficacy of hiatal closure for early GERD disease. The study team hypothesizes that hiatal closure for early GERD disease is an efficacious treatment of GERD.

NCT ID: NCT06222177 Recruiting - Clinical trials for Gastro Esophageal Reflux

Thresholds of SLR Maneuver in Obese Patients

SLR obese
Start date: January 1, 2024
Phase:
Study type: Observational

There is an increasing interest in High resolution manometry (HRM) in the preoperative assessment of patients with obesity, in order to identify the best surgical option. Sleeve gastrectomy (SG) has been known to increase the risk of gastro-esophageal reflux disease (GERD). Different techniques have been recently developed and validated to offer to these patients protection against pathologic GERD after SG. A recent study found a significant correlation between straight leg raise (SLR) maneuver during HRM and a positive pH-study. However, these maneuver has not been validated in an obese population, therefore the normality cut-off remain unknown. A multicenter study with a large number of patients undergoing pre-operative assessment for bariatric surgery could provide a precise threshold to predict pathologic esophageal acid exposure time.

NCT ID: NCT06025773 Recruiting - Clinical trials for Gastro Esophageal Reflux

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.

NCT ID: NCT05989698 Recruiting - Asthma Clinical Trials

C-mo System 1.0's Validation - Cough Monitoring

C-mo_01
Start date: December 11, 2023
Phase: N/A
Study type: Interventional

Cough is one of the most reported symptoms, especially associated with respiratory diseases. Additionally, cough contains extremely insightful information regarding the patient's health. It is a symptom full of physiopathological information, which can be extremely helpful in clinical practice. However, cough is not currently used as a clinical biomarker given that: 1. Cough is an extremely subjective symptom for patients (patients can't accurately describe and understand their cough's traits). 2. There is currently no tool available to evaluate cough objectively and thoroughly. As such, there is an unmet medical need: solutions for objective cough monitoring and management. C-mo System is a novel non-invasive medical device, which performs an objective monitoring of the patient's cough for long periods of time. The C-mo System consists of a wearable device (C-mo wearable) and a desktop software (C-mo Medical Platform). C-mo System characterises cough automatically through data collection and processing techniques (automatic classification), and its base outputs include: - Cough frequency (how many times the patient coughs) - Cough intensity (how strong cough's expiratory effort is) - Cough type (if the cough is dry, wet, or laryngeal) - Identification of patterns (associations between cough characteristics and specific events, namely the time of day, body position, physical exercising, and meals). It is extremely important to validate C-mo System in a wide and diverse population, given the use of signal processing algorithms and artificial intelligence. C-mo System's base outputs will allow healthcare professionals to improve significantly the medical care associated with this symptom, namely: - Speed-up and improve the accuracy of the diagnosis of several medical conditions, especially respiratory diseases. C-mo System's ability to objectively monitor cough will allow healthcare professionals to make associations between specific cough patterns and specific medical conditions. - Optimize treatment prescription and monitor their effectiveness. C-mo System's objective assessment of cough will allow healthcare professionals to understand if a given therapy is working as intended. - Objectively monitor chronic disease progression. C-mo System's monitoring of cough will allow healthcare professionals to objectively assess the progression of the patient's cough.

NCT ID: NCT05760274 Recruiting - Clinical trials for Gastro Esophageal Reflux

Esophageal pH-MII Duration: 12 or 24 Hours?

Start date: July 13, 2022
Phase:
Study type: Observational

To check whether the first 12 hours of MII-pH recording are sufficient to diagnose gastroesophageal reflux disease (GERD) among newborns/infants, with a diagnostic accuracy similar to 24 hours of recording as currently advised.

NCT ID: NCT05570448 Recruiting - Clinical trials for Gastro Esophageal Reflux

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

AREA21
Start date: February 15, 2022
Phase: N/A
Study type: Interventional

This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months. Patients must have a positive pH test and a negative manometry (no treatment) procedure.

NCT ID: NCT05359965 Recruiting - Clinical trials for Obstructive Sleep Apnea

Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

This study will evaluate the effect of CPAP therapy on esophageal pH and lung inflammation in patients with idiopathic pulmonary fibrosis (IPF) and sleep apnea.

NCT ID: NCT05204303 Recruiting - Clinical trials for Gastro Esophageal Reflux

LPR Fluorescence Pilot

Start date: July 1, 2022
Phase:
Study type: Observational

Comparing the fluorescence signatures from mouthwash samples of patients with laryngopharyngeal reflux (LPR) and healthy volunteers.

NCT ID: NCT05180253 Recruiting - Clinical trials for Gastro Esophageal Reflux

Esophageal and Gastric Registry and Biorepository

Start date: January 9, 2023
Phase:
Study type: Observational

The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract. We will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.